UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Not sure what you can access? Learn more about account types.

Introduction

British, Irish and European guidelines recommend interval re-evaluation of LA Grade C and D oesophagitis to identify occult malignancy and Barrett’s oesophagus.

Aims & Methods

We aimed to evaluate our service’s re-evaluation practice, identify factors which predict both malignancy and Barrett’s oesophagus, and determine our yield of re-evaluation.
We queried and cross-referenced our endoscopy and histology databases. Data analysis was conducted in Microsoft Excel and R Studio.

Results

1,700 index cases of Grade C/D oesophagitis were identified over 18.5-years ended November-2023. 62% were male. Median age was 62 (IQR:48-74). 717 had a first re-evaluation (42%).
6 cases were subsequently diagnosed with an oesophageal malignancy. Median age was 77.5 (IQR:50-83). 50% were male. Univariate binary probit logistic regressions identified neither age (≥70 years) (p=0.1), nor gender (p=0.55), nor Grade D oesophagitis (p=0.71) as predictors of malignancy.
Index histology was obtained in each case of malignancy. 3 of these malignancies (50%) were diagnosed on index histology. Of the remaining 3, 1 was diagnosed on a repeat 66-days later. The remaining 2 had non-revelatory re-evaluations, albeit without oesophageal histology, an average of 12.7 weeks later, and were subsequently diagnosed an average of 2.2 years later.
48 cases of occult Barrett’s oesophagus were identified on surveillance procedures, with a total of 183 when index identifications were included (10.8%), closely paralleling background population rates. No cases of occult dysplasia were identified in this context.

Conclusion

Our yield of Grade C/D oesophagitis re-evaluation over almost two decades was low despite the performance of 823 surveillance procedures at an approximate inflation-adjusted expenditure of €580,215.

References

Beg S, Ragunath K, Wyman A, et al. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS) [published correction appears in Gut. 2017 Dec;66(12):2188. doi: 10.1136/gutjnl-2017-314109corr1.]. Gut. 2017;66(11):1886-1899. doi:10.1136/gutjnl-2017-314109
Rodríguez-de-Santiago E, Frazzoni L, Fuccio L, et al. Digestive findings that do not require endoscopic surveillance - Reducing the burden of care: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy. 2020;52(6):491-497. doi:10.1055/a-1137-4721

LOS ANGELES GRADE C AND D OESOPHAGITIS: RE-EVALUATION OVER TWO DECADES AT AN IRISH TERTIARY REFERRAL CENTRE

Thomas Matthews 1, Colin Barry 1, Sarah Connor 1, Harry Tyrrell 1, Ryan Wilson 1, Aditya Billur 1, Gayle Bennett 1, Barry Kelleher 1, Conor Lahiff 1, Jan Leyden 1, Navneet Ramlaul 1, Stephen Stewart 1, Orla Craig 1

1 The Mater Hospital, Dublin, Ireland

Conference

UEG Week Berlin 2025

Topics

Oesophagus

Submission format

Abstract

Session

GERD (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Incidence and management of bile duct injuries

Dieter Broering 1

1 King Faisal Specialist Hospital & Research Centre (KFSH&RC), Riyadh, Saudi Arabia

Event

UEG Week Berlin 2025

Topics

Hepatobiliary Pancreas Surgery

Session

Post-OP complications: When do we need to step in?

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Autoimmune cholestatic liver disease: Differential diagnosis and management

Gerald Denk 1, Sabine Weber 1

1 LMU Klinikum, Munich, Germany

Event

UEG Postgraduate Teaching Programme Berlin 2025

Session

Autoimmune disease of liver and bile ducts

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Systemic sclerosis (SSc) is a rare and complex autoimmune disorder characterized by fibrosis of the skin and internal organs, as well as vasculopathy. The disease can be classified into two main subtypes: diffuse and limited. The diffuse subtype is more frequently associated with significant internal organ fibrosis. In the Asia-Pacific region, Thailand has the highest prevalence of systemic sclerosis, with an incidence of 24.4 per 100,000 population. Gastrointestinal involvement occurs in over 90% of patients with SScwith esophageal involvement being particularly common. Among these, gastroesophageal reflux disease (GERD) is present in approximately 80% of SSc patients. Erosive esophagitis (EE), a severe form of GERD characterized by the erosion of esophageal mucosa, is observed in about 80% of GERD cases. Its severity is classified according to the Los Angeles classification (grades A to D), with 30% of cases classified as severe (Los Angeles grades C and D). Proton pump inhibitors (PPIs) are currently the standard treatment for GERD and EE in SSc patients. However, fewer than 50% of patients demonstrate adequate response to PPIs therapy, highlighting the need for alternative treatments. Vonoprazan, a novel potassium-competitive acid blocker (PCAB), has emerged as a potent and longer-acting alternative to traditional PPIs. It has shown superior efficacy in treating severe erosive esophagitis in the general population. Previous cohort studies have demonstrated promising results with vonoprazan in improving symptoms and healing rates in SSc patients with refractory GERD up to 60% in refractory GERD; However, randomized controlled trials evaluating its efficacy in this population remain limited. This study aims to conduct a randomized controlled trial comparing the efficacy of vonoprazan and PPIs in treating erosive esophagitis in SSc patients.

Aims & Methods

The aim was to compare the efficacy of vonoprazan and lansoprazole in healing erosive esophagitis in patients with systemic sclerosis.
A randomized placebo-controlled trial was conducted in patients with systemic sclerosis (SSc) and refractory GERD who had erosive esophagitis confirmed by endoscopy. Participants were recruited from the systemic sclerosis clinic at Srinagarind Hospital, Khon Kaen University, from June 2024 to March 2025. Patients were randomized to receive either vonoprazan 20 mg once daily or lansoprazole 30 mg once daily for 8 weeks. The primary outcome was the percentage of healing at 8 weeks. Secondary outcomes included improvement in gastro-esophageal reflux disease (GERD) symptoms, as assessed by the Frequency Scale for the Symptoms of GERD (FSSG), GERD Questionnaire (GerdQ), and visual analogue scales (VAS) for heartburn and regurgitation.

Results

A total of 48 patients were enrolled in the study. The healing rates for vonoprazan and lansoprazole were 73.9% and 39.1%, respectively, resulting in an absolute risk reduction of 0.348 (95% CI: 0.081–0.614; p-value: 0.017). Subgroup analysis of patients with severe erosive esophagitis, defined as Los Angeles (LA) grades C-D, demonstrated that vonoprazan was superior to lansoprazole (75% vs. 33.3%; absolute risk reduction: 0.52; 95% CI: 0.167–0.873; p-value: 0.008). No significant difference was observed between the two treatments in patients with LA grades A-B.

Conclusion

Preliminary data suggests that vonoprazan was superior to lansoprazole in the healing of erosive esophagitis in systemic sclerosis patients, with this benefit being particularly evident in cases of severe erosive esophagitis (LA grades C-D).

References

1. Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Lancet. 2023 Jan 28;401(10373):304–18.
2. Foocharoen C, Ngamjarus C, Pattanittum P, Suwannaroj S, Pongkulkiat P, Onchan T, et al. Incidence and prevalence of systemic sclerosis in Thailand in year 2017-2020: a database from the Ministry of Public Health. Clin Rheumatol. 2023 Jul;42(7):1767–74.
3. Emmanuel A. Current management of the gastrointestinal complications of systemic sclerosis. Nat Rev Gastroenterol Hepatol. 2016 Aug;13(8):461–72.
4. McMahan ZH. Gastrointestinal involvement in systemic sclerosis: an update. Curr Opin Rheumatol. 2019 Nov;31(6):561–8.
5. Roth E, Bruni C, Petelytska L, Becker MO, Dobrota R, Jordan S, et al. Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort. Rheumatology. 2025 Jan 8;keaf016.
6. Denaxas K, Ladas SD, Karamanolis GP. Evaluation and management of esophageal manifestations in systemic sclerosis. Ann Gastroenterol. 2018;31(2):165–70.
7. Chunlertrith K, Noiprasit A, Foocharoen C, Mairiang P, Sukeepaisarnjaroen W, Sangchan A, et al. GERD questionnaire for diagnosis of gastroesophageal reflux disease in systemic sclerosis. Clin Exp Rheumatol. 2014;32(6 Suppl 86):S-98-102.

VONOPRAZAN VERSUS LANSOPRAZOLE FOR HEALING EROSIVE ESOPHAGITIS IN PATIENTS WITH SYSTEMIC SCLEROSIS (HEAL-SSC): A PRELIMINARY REPORT OF RANDOMIZED PLACEBO-CONTROLLED TRIAL

Rachaporn Kongbumrung 1, Tanita Suttichaimongkol 2, Wattana Sukeepaisarnjaroen 3, Pisaln Mairiang 1, Chingching Foochareon 1, apichat sangchan 1, Kookwan Sawadpanich 1, Chitchai Rattananukrom 1, Witsarut Manasirisuk 1

1 KhonKaen University, KhonKaen, Thailand

2 Srinagarind Hospital, Khon Kaen, Thailand

3 Faculty of Medicine, Khon Kaen, Thailand

Conference

UEG Week Berlin 2025

Topics

Oesophagus

Submission format

Abstract

Session

GERD (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Do we still need a liver biopsy to diagnose MASLD and vascular liver disease? Yes or no

Andrea De Gottardi 1, Valerie Paradis 2

1 Ente Ospedaliero Cantonale - Università della Svizzera Italiana, Lugano, Switzerland

2 INSERM - Hôpital Beaujon, Clichy, France

Event

UEG Postgraduate Teaching Programme Berlin 2025

Session

Metabolic and vascular disorders of the liver

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Portal hypertension is a major complication of advanced chronic liver disease (ACLD) and is associated with gastro-oesophageal varices, a leading cause of morbidity and mortality. The British Society of Gastroenterology (BSG) recommends oesophagogastroduodenoscopy (OGD) for variceal screening in all patients with cirrhosis, which could result in a high volume of unnecessary procedures. Given increasing demands on NHS services and the need for cost-effective resource allocation, strategies to reduce unnecessary endoscopy are critical.
The Baveno VI and VII consensus workshops propose non-invasive criteria to optimise variceal screening. Baveno VI suggests that patients with a liver stiffness measurement (LSM) less than 20 kPa and a platelet count greater than 150×10⁹/L can safely avoid OGD. Baveno VII further refines this by recommending non-selective beta-blocker (NSBB) therapy in patients with clinically significant portal hypertension (CSPH), defined as LSM greater than 25 kPa, thereby eliminating the need for screening endoscopy in this group. For patients not clearly stratified by Baveno VI or VII criteria, splenic stiffness measurement (SSM) offers an additional non-invasive tool to refine risk assessment. Incorporating SSM in this intermediate-risk group may further reduce the need for OGD, with recent data showing a high negative predictive value for ruling out high-risk varices.

Aims & Methods

We aim to quantify the reduction in endoscopy burden achieved by applying Baveno VI and VII criteria in ACLD patients.
A retrospective analysis was conducted on 1,703 patients who underwent 1,802 FibroScans between January 1, 2024, and December 31, 2024. Patients were stratified based on LSM and platelet counts into the following categories:
1. BSG Criteria: All patients with LSM ≥10 kPa requiring OGD.
2. Baveno VI Criteria: Patients with LSM <20 kPa and platelet count ≥150×10⁹/L, for whom OGD could be safely avoided.
3. Baveno VII Criteria: Patients with CSPH (LSM ≥25 kPa) recommended for NSBB therapy without the need for screening OGD.
4. Patients requiring OGD: Those not meeting Baveno VI criteria and without CSPH.

Results

Liver stiffness distribution:
• <10 kPa: 1,534 patients
• 10–14.9 kPa: 136 patients
• 15–19.9 kPa: 44 patients
• 20–24.9 kPa: 31 patients
• ≥25 kPa: 57 patients
Impact of Adopting Baveno VI and VII:
• BSG Guidelines: 274 patients (LSM ≥10 kPa) would require OGD.
• Baveno VI: 149 patients (LSM <20 kPa, platelets ≥150) could avoid OGD.
• Baveno VII: 57 patients (LSM ≥25 kPa) would be managed with NSBB, avoiding OGD.
• Total Reduction: 206 out of 274 patients (~75%) could avoid OGD.

Conclusion

Adopting Baveno VI and VII criteria would significantly reduce the need for variceal screening endoscopy in ACLD patients. By applying these thresholds, up to 75% of OGDs could be avoided, optimising NHS resources and reducing patient burden. These findings support the routine use of non-invasive risk stratification in ACLD management.

References

1. Tripathi D, Stanley AJ, Hayes PC, et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015;64(11):1680–1704. doi:10.1136/gutjnl-2015-309262
2. de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–752. doi:10.1016/j.jhep.2015.05.022
3. de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974. doi:10.1016/j.jhep.2021.12.022